Medicure is Persevering on the Prairies


I am a proud Manitoban, and not only do I cheer for the Jets, I cheer for all things Manitoba. I cut my life science teeth so-to-speak, as a drug rep covering Manitoba, Saskatchewan and Northwest Ontario – God’s Country. While completing an MBA at the Asper School of Business, I was recruited away from […]

The overlooked reason Target failed in Canada

A Target store in  Brossard, Quebec.

Target is currently wrapping up an expensive and embarrassing Canadian experiment. A liquidation of the company’s assets has been underway for nearly two months, and snapshots of its increasingly barren shelves have been a mainstay of media coverage since February. The U.S. retail giant decided to enter Canada in 2011, with the purchase of 220 […]

Can Alberta Get Off The Oil Roller Coaster?


Alberta brought down a budget on Thursday, featuring multi-billion dollar deficits for the next several years, tax hikes for the wealthy, program cuts for everyone, and the looming spectre of major job losses in the oil industry. Also happening last week in Edmonton was the World Heavy Oil Congress, probably the saddest, angriest place to […]

Epicore BioNetworks is a buy, says Cantor Fitzgerald Canada


Epicore BioNetworks (TSXV:EBN) has a credible plan to gain market share in a potentially massive market; the supply of sustainable sources of higher value proteins, says Cantor Fitzgerald Canada analyst Scott Curtis. In a research report to clients yesterday, Curtis initiated coverage of Epicore BioNetworks with a “Buy” rating and one year target of $1.65, […]

ViXS is still a buy, says Paradigm Capital


Following the company’s fourth quarter results yesterday, Paradigm Capital analyst Daniel Kim maintained his bullish stance on ViXS (TSX:VXS). Yesterday, ViXS reported its fourth quarter and fiscal 2015 results. In the fourth quarter, the company lost $3.8-million on revenue of $11.2-million, a 60% bump over last year’s $7.0-million Q4 topline. “In fiscal 2015, ViXS executed […]

theScore gets buy rating, $1.00 target at Mackie Research Capital


theScore (TSXV:SCR) is undervalued, says Mackie Research Capital analyst Nikhil Thadani. In a research report to clients today, Thadani initiated coverage of theScore with a “Buy” rating and a one year target price of $1.00, implying a return of 52% at the time of publication. Thadani says he likes the company’s move into fantasy sports […]

Bill C-51 is “more concerning” than CISA, says Mozilla

A protest of the proposed Bill C-51 in Calgary on March 14, 2015.

Canada’s proposed cyber security legislation, Bill C-51, will “erode the relationship between individuals and their government” by granting powers that are too sweeping in scope, says one notable watchdog of internet policy initiatives. Writing for Mozilla’s Open Policy & Advocacy blog, writer Jochai Ben-Avie compared the cyber security bill in front of the U.S. Senate […]

Pivot Technology has huge upside, says Cantor Fitzgerald Canada

Pivot Technology co-founder and former Apple CEO John Sculley.

Pivot Technology Solutions (TSXV:PTG) is a multi-vendor solutions provider with huge upside, says Cantor Fitzgerald Canada analyst Ralph Garcea. In a research report to clients this morning, Garcea initiated coverage of Pivot Technology with a “Buy” rating and one year target of $1.25, implying a return of 297% at the time of publication. Pivot was […]

How the Type-C Connector Could Revolutionize Electronic Devices

You gotta C this.

This report was adapted by Cantech Letter from a piece prepared by Sophic Capital. For the original report, and more in-depth research, please visit Sophic Capital’s website, here. Apple’s decision to replace three legacy ports on its next generation MacBook with the USB Type-C connector is evidence that this connector is about to disrupt the […]